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Abstract  
Deciphering regulatory events that drive malignant transformation represents a major challenge 
for systems biology. Here we analyzed genome-wide transcription profiling of an in-vitro 
transformation process. We focused on a cluster of genes whose expression levels increased as a 
function of p53 and p16INK4A tumor suppressors inactivation. This cluster predominantly consists of 
cell cycle genes and constitutes a signature of a diversity of cancers. By linking expression profiles of 
the genes in the cluster with the dynamic behavior of p53 and p16INK4A, we identified a promoter 
architecture that integrates signals from the two tumor suppressive channels and that maps their activity 
onto distinct levels of expression of the cell cycle genes, which in turn, correspond to different cellular 
proliferation rates. Taking components of the mitotic spindle as an example, we experimentally verified 
our predictions that p53-mediated transcriptional repression of several of these novel targets is 
dependent on the activities of p21, NFY and E2F. Our study demonstrates how a well-controlled 
transformation process allows linking between gene expression, promoter architecture and activity of 
upstream signaling molecules. 
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Introduction 
Cellular process are controlled by highly intricate regulatory networks (Bar-Joseph et al., 2003; 
Ihmels et al., 2002; Lee et al., 2002; Pilpel et al., 2001; Segal et al., 2003; Sharan et al., 2004; Sharan et 
al., 2003; Shen-Orr et al., 2002; Tavazoie et al., 1999; Werner, 2001). Most successes to date in 
understanding such networks were obtained in lower organisms; extension to mammalian genomes is 
complicated in part due to the complexity of the promoter and enhancer regions and also due to the 
tremendous intricacy of some of the regulatory circuits. Nevertheless, initial studies, e.g. in fly and in 
mammalian organisms succeeded in delineating promoter elements controlling specific to particular 
networks of genes (Berman et al., 2002; Berman et al., 2004; Elkon et al., 2003; Halfon et al., 2002; 
Smith et al., 2005; Sumazin et al., 2005; Thompson et al., 2004; Wasserman et al., 2000; Werner et al., 
2003; Zhu et al., 2005). One such relevant study is that of Elkon et al. (Elkon et al., 2003) who pursued 
genome-wide in-silico identification of transcriptional regulators controlling the human cell cycle. 
Recent studies (Segal et al., 2003) explored an additional level in the signaling network in yeast, 
namely links between gene expression profiles and activity of signaling molecules that may directly 
affect transcription. Here too, extension to higher organisms is complicated by the considerable 
increase in the intricacy of signaling network architecture. 
In addition to deciphering normal physiological processes, elucidation of regulatory and 
signaling networks is expected to allow better understanding of pathological conditions, such as cancer 
(Segal et al., 2004). Monitoring gene expression changes on a genome-wide scale is a powerful method 
to study transcriptional programs involved in carcinogenesis (Cho et al., 2001; Liotta and Petricoin, 
2000; Whitfield et al., 2002). Indeed, specific expression signatures that correlate with specific 
diagnosis, survival, and response to therapy were proposed (Liotta and Petricoin, 2000; Rosenwald et 
al., 2003; Scherf et al., 2000). Yet, associations of those signatures with specific biological processes or 
with distinct genetic alterations acquired by cancer cells along in-vivo transformations are not obvious. 
The difficulties largely stem from different genetic backgrounds of patients, variable and 
uncharacterized mutations in tumors, and the uncontrolled contribution of inflammatory, endothelial, 
and stroma cells, which contaminate tumor specimens, to the measured gene expression patterns. 
Thus, in order to obtain both novel and more reliable insights into genetic networks associated 
with oncogenesis, we have recently developed an in-vitro model for cellular transformation through a 
stepwise process (Milyavsky et al. 2003). The 600-day long transformation process (Fig. 1A) started 
with normal human diploid fibroblasts that entered replicative senescence after 40 population doublings 
(PDLs). In order to overcome replicative senescence, the cells were infected with human telomerase 
(hTERT), resulting in immortalization. After 150 PDLs following hTERT introduction, clones showed 
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an increased proliferation rate. At that stage, cells lost expression of the p16INK4A and p14ARF tumor 
suppressors (INK4A locus) (Milyavsky et al., 2003). To explore the transcriptional and phenotypic 
impact of p53 at different stages of the transformation process, the p53 protein was inactivated by 
expression of a dominant-negative p53 peptide (GSE56) (Ossovskaya et al., 1996). The combination of 
these genetic manipulations in conjunction with H-ras over-expression gave rise to cells capable of 
forming tumors in nude mice (Milyavsky et al., 2005). Recent studies have described similar 
inactivation of p16INK4A in additional human cell lines that overcame telomere-independent crises 
during immortalization (Taylor et al., 2004; Tsutsui et al., 2002). Furthermore, using various 
experimental models it was shown that full transformation could be achieved by the combination of 
viral oncogenes together with cellular genes (Hahn et al., 1999; Voorhoeve and Agami, 2003). 
Collectively, these experimental models generated a model of defined genetic aberrations that initiate 
and promote the neoplastic process.  
We have previously suggested that our in-vitro cellular system reproduces some of the distinct 
stages that characterize solid tumor initiation and progression (Milyavsky et al., 2005). In the present 
study we aimed at deciphering the specific transcriptional networks associated with defined stages of 
malignant transformation. Thus, we utilized genome-wide mRNA expression profiling recently carried 
out at 12 time points along the transformation process using the GeneChip Human Genome Focus 
Array (Affymetrix, Santa Clara, CA) that represents over 8,500 verified human sequences from the 
NCBI RefSeq database (Milyavsky et al., 2005). Subsequent cluster analysis of mRNA expression 
profiles identified ten stable clusters. One of them, termed the “proliferation cluster” (Milyavsky et al., 
2005), showed a pronounced sensitivity to the status of p53 and p16INKA tumor suppressors. 
Importantly, a large number of genes found in this proliferation cluster also clustered in studies that 
analyzed human primary tumor samples (Alizadeh et al., 2000; Barrett et al., 2003; Perou et al., 2000; 
Rosty et al., 2005). In addition, the proliferation cluster genes were found to be, on average, 
significantly more highly expressed in tumors obtained from patients with bad outcome compared to 
patients with good outcome in breast cancer (Dai et al., 2005; Milyavsky et al., 2005) as well as in 
other cancers (Tabach et al., in preparation). These findings strongly support the notion that the 
proliferation cluster genes are highly relevant to naturally occurring cancers.  
Here, we further analyzed the proliferation cluster in an attempt to reveal how the promoters of 
its genes generate a transcriptional program that integrates the activity of tumor suppressors within the 
cell. By linking expression profiles of the genes in the cluster with the dynamic behavior of p53 and 
p16INK4A, we identified two promoter architectures that integrate different signals from the two tumor 
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suppressive channels and that map their activity onto distinct levels of expression of the cell cycle 
genes, which in turn, correspond to different cellular proliferation rates.  
Results 
The "proliferation cluster" 
 Our recent cluster analysis of mRNA expression profiles during the cellular transformation 
process identified ten stable clusters (Milyavsky et al., 2005). According to the clustering method used 
(Blatt et al., 1996) a stable cluster is one which is robust against perturbing the data; on the one hand, 
the points that belong to it are (relatively) remote from other points, while, on the other hand, they 
constitute a well defined entity, i.e. a (relatively) contiguous region of high density of data points. The 
Super Paramagnetic Clustering algorithm we used is capable of grouping together points that constitute 
such a high density region, irrespective of the region's shape, and also provides a quantitative measure 
of the robustness or stability of our identification of these points as a "cluster".  
Here we focus on one of these clusters, which was a-posteriori termed the “proliferation 
cluster” (due to its genes annotations, see below). The cluster has a somewhat elongated shape, yet it is 
a stable and a well defined cluster that cannot be naturally divided into sub-clusters (Fig. S1). We 
decided to focus on this cluster since the genes that constitute it showed a complex and interesting 
behavior, i.e. pronounced, yet non-trivial (see below), sensitivity to the status of both p53 and p16INK4A 
tumor suppressors (Milyavsky et al., 2005).  
Fig. 1A shows a schematic description of the in-vitro transformation process. Fig. 1B shows 
expression profiles of the 168 genes of the proliferation cluster. Cells doubling rates for selected stages 
along the process are presented in the table below the expression matrix. Telomerase and p53 activity 
status are also shown. Four major states are distinguished. 1. The “young-cell period” (1st and 2nd 
columns in the expression matrix) corresponds to the early passages of cells and includes the first cell 
cycle divisions. During this period the cells are young and the expression profiles of the genes in the 
cluster are relatively high. At the second point during the young cell period (day 30) a separate cell 
culture was derived from the above culture by introduction of the p53 dominant-negative peptide, 
GSE56. The cluster genes responded by up-regulation (mean expression was significantly elevated 
from 406.5 to 479.5, P value = 3.1*10-23 by paired t-test). 2. The senescence period (3rd and 4th columns 
in the expression matrix) is characterized by arrest of cell divisions. The expression level of the genes 
in the cluster was dramatically decreased during this period. Yet, even within the senescence period, 
expression profiles of the genes in the cluster were significantly elevated at the 4th time point compared 
to the 3rd point, i.e. in response to p53 inhibition (p-value = 7.1*10-28 by paired t-test). 3. The “slow 
immortalization” period (5th - 7th columns in the expression matrix) is characterized by expression 
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levels similar to that in young cells. 4. The “fast immortalization” stage (8th  through 12th  columns in 
the expression matrix), which was shown to be associated with silencing of p16 (Milyavsky et al., 
2005), is characterized by a significant shortening of the cell cycle period (see table below expression 
matrix, Fig. 1B,). In parallel, a further increase in the expression levels of the cluster genes was 
observed. At the last two points of this period GSE56 was reintroduced, resulting in inhibition of p53. 
The genes in the cluster responded to p53 inhibition by significant (p-value = 1.4*10-32) up-regulation 
(column 11 and 12 in the matrix). It thus appears that the expression profiles of the genes in the 
proliferation cluster correlate with p53 activity as well as with the rate of cell proliferation.  
We next examined functional annotations of the genes in the cluster. Out of 168 genes of the 
cluster, 112 have functional annotation in “Gene Ontology” (Ashburner et al., 2000). All enriched 
functional terms among these genes, along with statistical significance analysis (Dennis et al., 2003) 
are listed in Table S1. Notably, only cell cycle-related functions are significantly (p-value <10-10) over 
represented in the cluster. A detailed examination of this gene cluster revealed that it includes mainly 
genes associated with various aspects of cell proliferation. We thus termed the cluster “the proliferation 
cluster”. The genes in the cluster take part in diverse processes crucial for the transition through the 
different cell cycle phases, such as DNA replication (MCM2, MCM3, MCM5, MCM6, RRM1-2, 
RFC3-5, GMNN, POLA, POLD1, POLE, POLQ, PRIM1) and DNA repair (BLM,BRCA1,MSH6). 
G2/M phase genes represented the largest functional category. More specifically, cyclin-dependent 
kinase CDC2, whose function is critical for mitotic entry, and its regulators such as cyclin B2, 
CDC25A, and CDC25C, showed marked up-regulation. In addition, genes with distinctive function in 
mitosis, including mitotic spindle organization (CENPA, CENPF, TTK, BIRC5, kinesins), mitotic 
spindle checkpoint (BUB1, BUB1B, MAD2L1, CDC20), and chromosome segregation (PTTG1, 
CENPF, ESPL1, UBE2C, PLK1, STK12) were also up-regulated upon p53 inactivation. This cluster 
also includes genes that are responsible for DNA packaging (HAT1, CHC1, SUV39H1, TOP2A) and 
chromosome organization (H1FX).  
Since many of the genes in the proliferation cluster belong to the core of the cell cycle 
machinery, we examined whether they display cell cycle periodicity using data from whole-genome 
mRNA profiles during HeLa cell divisions (Whitfield et al., 2002). We found that 53% of the genes in 
the proliferation cluster, for which expression data exists also in the HeLa cell cycle experiment, 
display a cell cycle periodicity (CCP) index (Tavazoie et al., 1999) greater than three (a score that 
corresponds to the top 6.7th percentile of all genes represented on the array). The expression profiles of 
these genes during cell cycle peak at the two main cell cycle checkpoints, namely the entry into the S 
and M phases (Fig. S2).  
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In summary, we found that the proliferation cluster is enriched with cell cycle periodic genes, 
whose functions are at the core of the cell cycle machinery. Expression of these genes peaks at the end 
of the transformation process in our in-vitro model, the only stage at which transplanted cells give rise 
to malignant tumors in mice. In addition, these genes are co-expressed in tumors derived from patients 
with various types of cancers, and show high correlation with poor outcome and prognosis (Milyavsky 
et al., 2005), attesting to their relevance to naturally-occurring cancers. 
Transcriptional regulation of the proliferation cluster genes 
We next turned to identify promoter regulatory motifs that drive the expression of genes in the 
proliferation cluster. Rather than attempting to discover de-novo promoter motifs, we assumed that 
transcription factors with previously elucidated binding sites may be involved in regulating the genes in 
the cluster. Therefore we searched within the promoters of the proliferation cluster genes for the 
presence of each of the 326 known vertebrate transcription factor binding sites, represented as position 
specific scoring matrices (PSSMs) in the MatInspector database (Quandt, 1995). For this analysis, we 
adopted a working definition of the promoter region as the genome sequence that spans 1000 base-pairs 
upstream of the transcription start site (TSS) of each gene (Materials & Methods). We used a gene-to-
PSSM assignment algorithm as in (Elkon et al., 2003) in order to scan each PSSM against the 
promoters of all genes represented on the array. For each PSSM, we calculated a hyper-geometric p-
value score (Hughes et al., 2000) to assess the extent to which a motif is over represented among the 
cluster’s genes compared to the rest of the genes on the array. We used the Bonferroni correction 
criterion for multiple hypotheses testing to set a threshold for over-representation of motifs in the 
cluster. Noticeably, all significant motifs, apart from VMYB, and including NFY, E2F, CHR (Cell 
cycle genes Homology Region), ELK1 and CDE (Cell cycle-Dependent Element), are known to be 
involved in the regulation of cell cycle (Badie et al., 2000; Bracken et al., 2004; Buchwalter et al., 
2004; Manni et al., 2001; Mantovani, 1998; Matuoka and Chen, 2002; Nevins, 2001). We therefore 
focused on these cell cycle motifs in all subsequent analyses. Table I. shows all PSSMs with 
statistically significant over-representation in the cluster (Table S5 shows statistics of all the motifs in 
MatInspector). We have also examined the presence of the motifs in the 5’ UTRs of the cluster’s genes 
and found only barely significant over-representations in the cluster (see Table S2), and have thus 
decided to concentrate on the upstream regions only in all further analyses. 
Evolutionary conservation of the motifs 
 We examined promoters of mouse genes orthologous to the proliferation cluster genes and 
found that the same motifs are also significantly over-represented in these promoters compared to the 
promoters in the rest of the mouse genome (Table S3). We have further assessed conservation at an 
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organization level beyond the mere presence/absence of motif, namely conservation of the motif 
architecture between the two species. We found considerable conservation at this level too, using two 
criteria: First, the combinations of motifs that regulate orthologous promoters were significantly more 
similar to each other compared to combinations of non-orthologs (Fig. S3, A). Second, we found a 
significant tendency to preserve the locations of the motifs relative to the transcription start site in 
orthologous promoters (Fig. S3, B-F). The high level of conservation observed attests to the functional 
role of the motifs in these promoters. 
Revealing a hierarchy of regulatory motif combinations 
Having found a set of regulatory motifs that likely control the expression of the genes in the 
proliferation cluster we next attempted to identify particular combinations of such motifs. Here and in 
subsequent analysis a motif was considered present in a promoter if it appeared in the motif’s preferred 
distance relative to the transcription start site, as shown in Fig. 2 (and see Materials and Methods). To 
this end, we calculated the “synergy” (Banerjee and Zhang, 2003; Garten et al., 2005; Pilpel et al., 
2001) and rate of co-occurrence (Elkon et al., 2003; Sudarsanam et al., 2002) between regulatory 
motifs. A pair of motifs was considered 'synergistic' if the extent of expression coherence (Lapidot and 
Pilpel, 2003; Pilpel et al., 2001) of genes containing both motifs in their promoters is significantly 
greater than that of genes containing either of the motifs alone (Pilpel et al., 2001). A pair of motifs was 
considered highly co-occurring if there is a significant overlap between the set of genes containing the 
two motifs, given the number of genes containing each motif, and the genome size (using a hyper-
geometric test to assess significance of overlap). In a recent study in yeast, we showed that although the 
two measures need not necessarily correlate, they are largely congruent in reality (Garten et al., 2005). 
We found that NFY, E2F, CDE, and CHR show multiple mutual interactions with each other, many of 
which were supported by both synergy and co-occurrence. On the other hand, the ELK1 motif co-
occurs significantly with E2F and CDE, yet it has no synergistic effect with other motifs on gene 
expression (Fig. 3A). Many of the interactions are observed also when only genes in the proliferation 
cluster are considered (Fig. 3A). 
In order to gain more insight on such motif interactions we used the Combinogram analysis, 
which we have previously utilized to dissect regulatory networks in yeast (Pilpel et al., 2001). We 
searched for the above five regulatory motifs within the promoters of all varying genes represented on 
the array. Given the five regulatory motifs, we partitioned the genes represented on the array, for which 
we also had promoter sequence assignment, into up to 25 =32 non-overlapping gene sets, each defined 
by a unique binary signature that reflects the presence or absence of each of the five motifs in their 
promoters. In the Combinogram we group together genes with identical binary signatures, depict their 
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motif content (in the binary black & white matrix), the similarity between the average expression 
profiles of all pairs of gene sets (upper part dendrogram), and the averaged expression profiles of the 
genes in each set (expression matrix at the bottom part). The Combinogram in Fig. 3B, which was 
obtained with 18 gene sets that were populated with genes (14 other potential sets were not populated 
with genes), reveals several clear trends. First, although the analysis was applied to the entire set of 
genes represented on the array, i.e. without any preceding clustering stage, a division (corresponding to 
the main branching point of the dendrogram, marked “1” in the dendrogram) into genes that contain 
some of the motifs, and genes that do not, appears. Gene sets that are to the left of branch point “1” 
largely represent the proliferation cluster signature, whereas gene sets that are on the right branch 
display more or less flat expression profiles with no particular trend. The motifs that appear to 
determine this split are mainly ELK1, or NFY & CHR. Genes that contain none of the five motifs 
(column #14 from left), display the flat profile, as do genes that contain one or two of the motifs, but 
not ELK1 (columns 11 through 18 from left). The left branch, that largely shows the proliferation 
signature, may be further divided (branch point “2”) into gene sets that contain at least ELK1 (columns 
1 through 8) vs. gene sets that contain NFY and CHR, but not ELK1. These differences in motif 
composition reflect themselves at the expression patterns – without ELK1 a clear decrease in 
expression in the senescence (40) and senescence GSE (4) time points (3rd and 4th rows of the 
expression matrix) is seen, whereas an increase in expression in the last two time points is evident too. 
The presence of ELK1 appears to be both necessary and sufficient for its typical dictated expression 
pattern, genes that contain only ELK1 (and none of the rest of the four motifs, column 5) are members 
of the ELK1 cluster, and genes that do not contain ELK1 (columns 9-18) are not in the cluster. Branch 
point “3” further sharpens the ELK1-dictated signal, as ELK1 show an interesting interaction with 
NFY. Genes that contain ELK1 and NFY (columns 6 through 8) are located to the right of branch point 
“3”, as they display an intermediate between the pure ELK1 pattern and the NFY&CHR pattern, while 
genes to the left of this branch point display a distinct pattern. In general this analysis shows a sticking 
correspondence between motif content and gross and fine differences in expression, akin to a previous, 
yet much simpler observation, made in yeast (Pilpel et al., 2001). It allows the dissection of the role of 
individual motifs and their combinations (e.g. the effect of CHR on the background of NFY and CDE 
is clear from the difference in expression patterns between columns 10 and 11 in which CHR is present 
and absent respectively). This analysis strongly suggests that indeed the five regulatory motifs 
examined here indeed govern gene expression profiles during the 600-day long malignant 
transformation process and that the proliferation signature represents a genuine response dictated by 
these motifs.  
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Next, we examined whether it is possible to trace the regulatory effect of these motifs down to 
the relatively microscopic time-scale of single cell cycle divisions. We therefore tested whether the 
motif architecture we discovered here also governs the expression of these genes during cell cycle 
divisions. To this end, we constructed a Combinogram based on the five motifs together with cell cycle 
expression data derived from the HeLa cell cycle experiment described above ((Whitfield et al., 2002), 
Fig. 3C). Notably, we observed similar relationships between motif combinations and their effects on 
expression in both the transformation and the cell cycle experiments. As in the transformation process, 
in the cell cycle too, NFY appears to interact synergistically with CHR, an interaction that gives rise to 
a clear G2-M phase expression pattern. Here the presence of the CDE motif further amplifies this 
pattern. The resemblance between the transformation and the cell cycle experiments indicates that the 
transcriptional regulation of the cluster during the complex and largely uncharacterized 600-day long 
transformation process can be reduced to the more ‘atomistic’ level of the regulation of cell cycle. 
Interestingly though, in the cell cycle experiment we did not detect any clear pattern dictated by E2F, 
alone, or through combinations with other motifs, suggesting either that despite intensive research on 
this transcription factor, an accurate description of its binding site is still missing, or that its regulatory 
role is too complex and diverse (Bracken et al., 2004). This too is consistent with a recent observation 
(Elkon et al., 2003) that although E2F is over-represented in the promoters of cell cycle genes, it is not 
restricted to genes that peak at specific cell cycle phase. Likewise, the ELK1 motif does not seem to 
affect gene expression throughout the cell cycle. The observation that the E2F and ELK1 motifs affect 
transcription mainly in the transformation experiment and less so in cell cycle may indicate that their 
role in the transformation process is not mediated through a direct effect on the cell cycle, but rather on 
a potentially higher level. Another potential explanation for the fact that presence of either ELK1 motif 
or the combination NFY and E2F was significant in the transformation experiment but not in HeLa cell 
cycle experiment may be related to the fact that in HeLa cells, both p53 and pRb are inactivated by the 
viral oncoproteins E6 and E7. Thus, if the ELK1 motif or the combination of NFY and E2F potentially 
mediate growth restrictive effects of these major tumor suppressive pathways, we would not expect 
these effects to be manifested in HeLa cells.  
The proliferation cluster genes integrate information from two tumor suppressive channels 
 Our knowledge of the detailed molecular history of the transformation process in the in vitro 
model allowed us to extend our analysis beyond the formation of links between regulatory motifs and 
expression profiles. Since the activity of upstream tumor suppressors was manipulated and monitored 
during the transformation, we could link gene expression patterns, mediated by various regulatory 
motifs, to expression levels of these signals. The activity levels of two prime tumor suppressor genes, 
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p53 and p16, varied throughout the transformation process. Since p53 was inactivated at the protein 
level, we used as a surrogate for its activity, array-derived mRNA measurement of its regulated target, 
p21, which is indeed down regulated after each application of the p53 dominant negative peptide, 
GSE56.  
First, we observed that while the averaged mRNA profiles of the genes in the proliferation 
cluster do not correlate with the mRNA levels of either p21 or p16 alone, they show high negative 
correlation (r = -0.85, the probability of pairs of random genes that are summed up as with p21 and p16 
to obtain such correlation or lower with the proliferation cluster’s average, is <1% as estimated by 
10,000 random samples of pairs) with a profile obtained by summing the mRNA expression profiles of 
these two genes (Fig. 4A). Simple logical functions such as AND or OR gates were unable to describe 
accurately the thresholded activity levels of the genes in the cluster as a function of the mRNA 
concentration of p16 and p21 (using various thresholds on their activity). Instead, the relationship can 
be accurately modeled with a “sum-gate”, namely the summated profiles of p21 and p16. The 
proliferation cluster genes thus appear to sum up the expression levels of the two tumor suppressors 
and produce an analog output in the form of expression profiles. Recently, similar sum-gated promoter 
architectures were observed in E. coli (Kalir and Alon, 2004; Setty et al., 2003).  
More importantly, we then identified the promoter motifs that likely mediate such integrative 
function. Based on our results with the proliferation cluster, we analyzed separately all the genes 
represented on the array that contain in their promoters the ELK1 motif, and all genes that contain a 
combination of NFY and CHR (The two motif combinations that dictate distinct expression patterns 
throughout he transformation process). Fig. 4B shows that the CHR&NFY-regulated genes clearly 
depend on both tumor suppressors, and their expression levels map the presence/absence of the two 
suppressors onto four distinct expression levels (multiple t-tests on all six pairwise comparisons always 
yielded significant p-value, with the least significant p-value equal to 0.0014*10-4). In contrast, the 
ELK1 motif mainly mediates a response to the presence/absence of p16. The expression of ELK1-
regulated genes is significantly up-regulated following p16 inactivation. Although the ELK1 
transcription factor was previously implicated in the regulation of expression of proliferation genes 
(Gille et al., 1995; Ullrich and Schlessinger, 1990), its potential regulatory interaction with either p16 
or p53 was not addressed before.  
Three-way linkage of expression, promoter architecture and tumor suppressor activity 
In order to gain further insights into the relationship between mRNA expression profiles and 
promoter architecture, we sorted the proliferation cluster genes using SPIN (Tsafrir et al., 2005), a 
sorting algorithm that positions genes with similar expression profiles in adjacent rows of an expression 
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matrix (Fig. 5A). We also examined the presence of the regulatory motifs in promoters of genes in the 
cluster along the sorted expression matrix (Fig. 5C and D). Interestingly, the CDE and E2F motifs are 
relatively evenly scattered along the cluster. Taken together with the observation that they are 
significantly highly specific to the proliferation cluster suggest that these motifs are major constituents 
of the entire cluster. On the other hand, the CHR motif, and to a smaller extent the NFY motif, are 
mainly concentrated in promoters of genes in the “upper” part of the sorted cluster, while ELK1 mainly 
shows a preference towards the genes in the “lower” part. We thus conclude that while CDE and E2F 
constitute the cluster and are present in the majority of its genes, CHR, NFY and ELK1 serve to 
modulate the general expression patterns dictates by CDE and E2F. 
Although the averaged expression profile of the cluster genes is strongly negatively correlated 
with the summated expression profiles of p16 and p21, but not with the individual tumor suppressors 
(Fig 4A), it is still possible that part of the genes only correlate with p21 while others only correlate 
with p16. We have thus measured (Fig. 5B) for each gene in the (sorted) cluster the correlation of its 
mRNA expression profile during the transformation process with the expression profiles of p16, p21 
and with the summated profiles of p21 p16 (Fig. 5B). Strikingly, for the majority of the genes in the 
cluster the negative correlation with the summated profile is stronger than with the individual tumor 
suppressors. This is predominantly true for the genes in the “upper” part of the sorted cluster. Although 
for these genes there exists also a negative correlation with p21 alone, they are more strongly 
(negatively) correlated with the sum-gate, suggesting that the motifs regulating these genes are indeed 
integrating, by summing up, the information from the two suppressor channels. The correlation with 
p21 gradually diminishes with genes that are located towards the "lower" part of the cluster and on the 
other hand the correlations with p16 level show the opposite trend, namely a high correlation with 
genes in the lower part of the cluster. We stress that the data suggest no obvious point where the cluster 
can be sub-divided in two clusters based on correlations with the two tumor suppressors.  
It was found recently that DNA binding activity of NFY transcription factor is positively 
regulated by CDK2 phosphorylation. This may explain the higher sensitivity of  NFY-containing genes 
to p21 level as it specifically inhibits CDK2 (Hahn and Weinberg, 2002; Sherr, 1996; Sherr and 
Roberts, 1999; Weinberg, 1995). On the other hand, p16 specifically inhibits CDK4 and CDK6 (Hahn 
and Weinberg, 2002; Sherr, 1996; Sherr and Roberts, 1999; Weinberg, 1995). Thus, the increased 
sensitivity of ELK1-containing promoters to p16 levels enables us to propose novel role for CDK4/6 in 
ELK1 regulation.  
The integration of these findings together with published experimental data allowed us to 
propose a network linking three layers of data – mRNA expression, promoter regulatory 
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motifs/transcription factors, and the upstream tumor suppressors and signaling molecules (Fig. 5E). It is 
entirely possible though that additional tumor suppressors and transcription factors participate in the 
network and future analysis may reveal their identity and role. 
Experimental validation of computational predictions  
Our data suggested that the proliferation cluster genes are potential targets of p53- and p16- 
mediated transcriptional repression. Notably, many cluster genes including TOP2A, CCNB2, CCNA2, 
BIRC5, CDC2, CDC25C, PRC1, POLD1, PLK and others were previously shown to be downregulated 
by p53 (Burns et al., 2003; Hoffman et al., 2001; Krause et al., 2000; Li et al., 2004; Manni et al., 2001; 
St Clair et al., 2004; Tang et al., 2001; Wang et al., 1997; Yamamoto et al., 1994; Yun et al., 1999), 
validating our analysis and enabling us to propose numerous novel p53-transrepression targets. 
Interestingly, multiple components of the kinetochore complex and most of the known spindle 
checkpoint genes are found in our proliferation cluster. Since p53 was not previously implicated in the 
regulation of this group of genes, we decided to test for p53-mediated transcriptional repression of 
several genes from this functional category. Importantly, the regulatory network we proposed, based on 
the microarray experiment conducted under basal unstressed conditions, is expected to hold for cases 
where the upstream tumor suppressors are induced either by forced overexpression or by stress. We 
therefore tested whether a stress-induced p53 will repress the expression of several kinetochore/spindle 
genes. To this end, we treated normal and GSE56-expressing WI-38 cells with doxorubicin, a DNA-
damaging agent and a potent p53 activator, and measured the levels of several proliferation cluster-
derived genes by quantitative real-time PCR (qPCR). Confirming our hypothesis, we found that 
following DNA damage, Cdc20, Bub1, CCNF, and Mad2L1, all of which are cluster members, were 
downregulated in normal WI-38 cells, but not in their isogenic counterparts, in which p53 was 
inactivated (Fig. 6). Thus, these kinetochore- and spindle checkpoint- related genes represent novel 
targets of p53-mediated transcriptional repression. 
Since our computational analysis revealed that the proliferation cluster genes display a negative 
correlation with p21 mRNA profile, we tested whether p53 exerts repression of proliferation cluster 
genes via p21 induction.  To this end, we treated the HCT-116 colon carcinoma cells and their p53-null 
and p21-null derivatives with doxorubicin. We measured the expression levels of several proliferation 
cluster genes by qPCR and calculated the fold repression for each gene as the ratio of expression level 
in non-treated cells to that in doxorubicin-treated cells (Table II). Notably, only cells that contained 
both functional p53 and p21 (HCT-116 p53+/+) displayed down-regulation of these genes following 
DNA-damage. This supports the notion that the proliferation cluster genes are transcriptionally 
repressed by p53, and suggests that this repression is mediated through p21.  
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In order to gain further insights into the mechanism of p53-dependent repression of the 
proliferation cluster genes, we decided to focus our efforts on the cdc20 gene as a representative 
member of the cluster. We cloned the cdc20 promoter into a luciferase reporter vector and transfected it 
into HCT-116 p53-/- cells with or without a p53 expression plasmid. As indicated in Fig. 7A, in the 
presence of wild-type p53, the activity of cdc20 promoter was significantly repressed. In contrast, a p53 
mutant lacking a functional transactivation domain (L22Q/W23S) did not repress cdc20. The 
requirement for a functional transactivation domain supports our conclusion that cdc20 repression by 
p53 is indirect and is mediated by induction of a mediator gene. Co-transfection of cdc20 promoter 
reporter with the p16 expression vector also resulted in repression of promoter activity (Fig. 7A), 
supporting our prediction that the proliferation cluster genes integrate signals from both p53 and p16. 
Since promoters of the proliferation cluster genes are highly enriched with E2F motifs, we 
tested whether cdc20 promoter activity is affected by the presence of an E2F1 dominant negative 
protein (E2F-dTA) that is capable of DNA binding but defective in its transactivation and RB-binding 
domain. Overexpression of this construct displaces the endogenous E2F proteins from the DNA, 
abolishing both activation and repression by E2F family members (Hofmann et al., 1996). As 
demonstrated in Fig. 7B, cdc20 promoter activity decreased in the presence of a dominant-negative 
E2F1, and p53 did not repress it further under those conditions (see Figure legend for details). The 
most significantly enriched motif in the proliferation cluster promoters is NF-Y, suggesting the 
involvement of its cognate transcription factor in the regulation of the cluster's genes. To validate this 
hypothesis, we tested whether cdc20 reporter activity is affected by the presence of an NF-Y dominant 
negative protein (Mantovani et al., 1994). Indeed, overexpression of a dominant negative NF-YA 
(dnNF-YA) resulted in reduction of cdc20 promoter activity and in strong attenuation of the p53-
dependent repression of this promoter. These results indicate that both the E2F family of transcription 
factors and the NF-Y transcription factor participate in cdc20 regulation, and that p53-dependent 
repression of cdc20 is mediated through these proteins. 
 Finally, we addressed the significance of the NF-Y motifs found in the cdc20 promoter for p53-
mediated repression. Two NF-Y motifs reside in cdc20 promoter within the first 100 bp relative to the 
TSS. We generated cdc20 promoter reporter constructs that harbor mutations in each of the motifs and 
an additional construct with both NF-Y motifs mutated. These constructs, together with the wild-type 
promoter, were tested for their responsiveness to p53 status by cotransfecting them into HCT-116 
p53+/+ cells in the presence or absence of a dominant-negative p53. While mutation of each NF-Y site 
alone did not affect p53-mediated repression (data not shown), mutations in both NF-Y motifs resulted 
in significant attenuation of the repression (Fig. 7C). These results support our computational 
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prediction that NF-Y motifs, enriched in the promoters of the cluster genes, are involved in the 
regulation of these genes by p53.  
Discussion 
This study describes the analysis of genome-wide expression profiles of an in-vitro 
transformation process. Focusing on a well-defined expression cluster that consists predominantly of 
core cell cycle genes, we identified promoter motifs and their combinations that regulate the 
transformation process. We suggest that at least part of such regulation can be explained by a direct 
effect on cell cycle progression. Working with a controlled transformation process allowed us, for the 
first time, to not only establish a connection between gene expression and promoter architecture, but 
also to identify links to the activity of upstream tumor suppressors. Such a three-way connection was 
most revealing as it identified promoter motifs that likely “count” the number of active tumor 
suppressive channels and map them onto distinct expression states. Finally, detailed experimental 
analyses of selected genes experimentally established many of the suggested components of the 
network.  
It is well known that activation of p53 leads to induction of p21 and inhibition of CDK2 activity 
(Hahn and Weinberg, 2002; Sherr, 1996; Sherr and Roberts, 1999; Weinberg, 1995). As depicted in Fig 
5E, CDK2 controls E2F indirectly (through inactivation of RB by phosphorylation) and NFY directly 
(through CDK2-mediated phosphorylation). The CHR (cell cycle genes homology region) and the CDE 
(cell cycle-dependent element) represent  "orphan" binding sites as the factors that bind these motifs 
are still un-cloned (Zwicker et al., 1995). These two elements are often found in close proximity to 
each other and these CDE/CHR "tandems" were shown to be important for the cell cycle-dependent 
expression of many genes. However, not always these two sites appear together. For example, a single 
CHR was shown to control cell cycle-dependent transcription of the cdc25C phosphatase gene and  to 
cooperate with E2F or Sp1/3 sites (Haugwitz et al., 2002). Our genome-wide analysis strongly suggests 
the existence of a novel strong functional cooperation between CHR and NFY elements. According to 
our Combinogram analysis, the presence of these two sites in the proximal 200 bp upstream of the 
transcription start site is sufficient to dictate a G2/M expression pattern of multiple genes (Fig. 3C). In 
addition, we discover here that the same promoter architecture, namely the combination of NFY and 
CHR, is responsible for the integration of inputs from p21 and p16 during the in-vitro transformation 
process.  
ELK1 transcription factor is a well-known downstream target of the MAP kinase pathway. It 
was demonstrated that proliferative inputs from deregulated MAP kinase pathway are counteracted by 
a negative feedback loop involving p16 activation with subsequent inhibition of CDK4/6 activities (Lin 
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et al., 1998; Serrano. M et al., 1997; Zhu et al., 1998). Interestingly, our results indicate a strong 
negative correlation between the activities of ELK1-containing promoters and the expression level of 
p16, suggesting a possibility that p16 inhibits the activity of ELK1. To the best of our knowledge, this 
relationship was not reported previously. Since p16 specifically inhibits CDK4 and CDK6, it is 
possible that phosphorylation by these kinases plays a role in ELK1 regulation.  
The two tumor suppressors studied here, namely p53 and p16, mainly respond to intrinsic and 
environmental signals, respectively. Thus, the promoter architecture discovered in this study integrates 
internal and external signals that affect core cell cycle genes. Such integration is performed by 
identifying and counting the number of active suppressive channels and mapping the result onto 
distinct expression levels. The intermediate expression level states, which correspond to precisely one 
active suppressive channel, may represent an "undecided" state. Such a state might be followed by 
either the high or low expression states of the cell cycle genes that may ensue after inactivation or 
activation of the second channel, respectively. Residing in such intermediate state can facilitate more 
rapid transition to one of the two extreme stages in response to addition or removal of intrinsic or 
environmental suppressive signal. In this respect it is crucial to note that the expression levels of the 
cluster's genes are correlated with proliferation rate (Fig. 1B); thus, promoter tuning of transcription of 
at least some the genes may affect proliferation. Many genes in the proliferation cluster represent 
previously identified targets of p53-mediated transcriptional repression. Our results significantly 
broaden the list of potential p53 transrepression targets. Here, for example, we identified an entire set 
of kinetochore/spindle genes, the expression of which is negatively regulated by p53. The functional 
significance of this finding is still unclear but it is tempting to speculate that loss of this transcriptional 
control contributes to aneuploidy formation, which is frequently found in tumors with mutated p53.   
An additional important conclusion of our study relates to the mechanism of p53-mediated 
transcriptional repression. Unlike transactivation by p53, which clearly requires p53 binding to the 
regulatory sequences of targets, the mechanisms of repression by p53 are less well understood. The 
promoters of repressed genes usually do not contain the p53 consensus binding sites. Various 
mechanisms of p53 transrepression were proposed for different genes.  These include interference with 
the functions of activators either involving p53 binding to DNA or through protein-protein interactions, 
direct interference with the basal transcription machinery, or recruitment of histone deacetylases and 
chromatin remodeling (for review see (Ho and Benchimol, 2003)). In addition, it was recently 
demonstrated for several genes that p53-mediated transcriptional repression requires the induction of 
p21 (Lohr et al., 2003). 
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Our study is the first to address the question of the mechanism that underlines p53-mediated 
repression in a more systematic way, using a three-way linkage of gene expression, promoter 
architecture and tumor suppressor activity. Our results strongly suggest that transcriptional repression 
by p53 is in most cases indirect and is mediated by p21 induction, which is transduced to E2F/CDE, 
NF-Y, and CHR motifs in the promoters of target genes. In addition we propose that overexpression of 
"proliferation signatures", found in a variety of aggressive human cancers, is frequently a consequence 
of p16 and p53 tumor suppressor inactivation. 
 Finally, it is very crucial to note that the proliferation signature described here has clear 
relationship with naturally occurring human tumors. Rosty and colleagues (Rosty et al 2005) have 
identified a cluster of genes (also named “proliferation cluster”), whose expression levels were 
predictive of outcome in samples derived from human patients with cervical cancer; low levels of 
expression characterized a subset of the patients with good outcome.  In our previous work (Milyavsky 
et al., 2005), we have shown that there is a significant overlap between our proliferation cluster and that 
reported by Rosty et al., and  we mentioned there other publications that reportded that many of our 
proliferation cluster genes constitute very good predictors of relapse vs. favorable outcome. These 
results demonstrate that the present proliferation signature, albeit obtained in vitro, has a strong 
predictive value regarding aggressive tumor behavior. However, we are aware of the fact that such 
common features should be carefully evaluated using additional types of naturally occurring 
malignancies. In addition, in the future, similar transformation processes, performed with additional 
cell lines and settings may be important for further establishing the generality of the signatures derived 
here. In that respect we note that in our previous work (Milyavsky et al., 2005) we addressed this issue 
by monitoring similar molecular events, such as INK4A locus inactivation in two additional cultures, 
thus supporting the generality of our findings. 
Materials and Methods 
Promoter sequence 
DNA sequences upstream of human ORFs were downloaded from the GoldenPath server at 
UCSC http://genome.ucsc.edu/goldenPath/hg16/bigZips/. Putative regulatory regions (1000 bps 
upstream to transcription start site) for the different genes were obtained. We used for the original 
experiment (Milyavsky et al., 2005) the GeneChip Human Genome Focus Array (Affymetrix, Santa 
Clara, CA) that represents over 8,500 verified human sequences from the NCBI RefSeq database. We 
identified promoters for 8110 genes out of the 8,500. Of the 8110 genes we have selected 5582 genes 
that had a "present call" (according to Affymetrix calling procedure) in the two duplicates of at least 
one sample. Of the 168 genes in the proliferation cluster, 141 probe sets had a promoter in GoldenPath. 
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When more than one probe set on the array corresponded to same genomic locus (e.g. due to alternative 
splicing) we considered the corresponding regulatory region only once. 
 While the present analysis covers only the 8,500 genes represented on the GeneChip Focus 
Array that was used in our original experiment (Milyavsky et al., 2005), we have also examined the 
promoter motif content of all ~33,000 genes that were represented on the U133 Array (Affymetrix, 
Santa Clara, CA). We found additional 2316 genes that were not represented on the Focus Array that 
contain at least 2 of the discovered transcriptional modules; 36 of them contain 4 of the motifs analyzed 
here, see Table S4. These genes may represent additional candidates for the network discovered here. 
A collection of Position Specific Scoring Matrices (PSSMs) 
We used the MatInspector library of 326 PSSMs maintained by Genomatix (Release 4.1) 
(Quandt, 1995) and a customary promoter to PSSM assignment score (Elkon et al., 2003). We have 
then identified a threshold on this score, above which a PSSM is considered assigned to a promoter. 
For that we used the genes in a cluster and for a range of potential values of the threshold score we 
calculated, using the hyper-geometric statistic, the groups specificity score (Hughes et al., 2000) of the 
motif relative to the genes in the cluster. We identified and adopted the threshold score that minimizes 
the hyper-geometric probability function. See Fig. S5 for examples for threshold score determination 
for a selection of motifs. Only motifs that passed the Bonferroni correction for multiple hypotheses 
testing (that considered the multiple attempted thresholds) were retained. 
Assessing motif positional bias 
Positional bias was previously defined as the extent to which a motif that is assigned to a set of 
promoters is enriched in a sequence window (defined in terms of distance relative to the TSS) of a 
fixed length (e.g. 50 bps) with the maximal number of promoter (Hughes et al., 2000).Although 
efficient and simple, this algorithm has a limitation of having to define a fixed length window, without 
a priori knowledge about the relevant window width. We thus devised the following alternative 
procedure that learns the window’s width from the data. We search for the window that is most 
enriched with occurrences of the motif using the following procedure: 
1. Assume we have N occurrences of the motif in the promoters of the cluster's genes. Denote their 
(ordered) distances from the TSS (of each gene) by Ci (i=1..N),  such that : 0 ≤ C1 ≤ .. ≤  CN < 
1000.   
2. A window is defined as a subinterval . We search for the window most enriched 
with motifs, compared to a random background model. For each window [a,b], we denote by 
M(a,b) the number of motifs Ci with distance of at least a and no more than b from the TSS. 
]1000,0[],[ ⊂ba
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The background distribution of the number of motifs in the window [a,b] is M(a,b) ~ 
Binomial(N, (b-a+1)/1000). Since windows overlap, an enrichment of a specific window leads 
to enrichment of windows overlapping it. Thus, we defined the most enriched window to be the 
one with smallest background probability, that is the interval [a,b] minimizing Pr(M(a,b)) under 
this background model.  Obviously, the densest window is [Ci , Cj] for some i≤j, therefore we 
can restrict our search only for intervals of the form [Ci , Cj].  Thus, it is defined as Wmin  = 
argmin,i,j Pr(M(Ci,Cj) ≥ j-i+1), with Pmin =   min,i,j Pr(M(Ci,Cj) ≥ j-i+1)).   
3. To test statistical significance of the densest window, the distribution of Pmin in the background 
model is required. This was calculated by simulations. For N from 2 to 300 we have performed 
100,000 simulations, each time selecting N points randomly in [0,1000] and then computing 
Pmin. This gave an empirical distribution denoted FN,min. The p-value for the observed most 
enriched window is simply FN,min (Pmin).  
Combinogram analyses 
The analysis was initiated with a set of N motifs. Each of the 5582 genes was assigned with a 
binary signature of length N with a 1 at the ith position if the gene contains motif i in its promoter, and a 
0 otherwise. Thus, 2N gene sets (that constitute the ‘power set’ of the set N), termed Genes defined by 
Motif Combinations (GMCs) were generated where all the genes in a given GMC share the same 
subset of the N motifs. The averaged expression profile of all the genes in each GMC was determined. 
The normalized Euclidian distance between averaged expression profiles for all pairs of GMCs was 
calculated and served as the input for the dendrogram analyses that were generated with the Cluster 
Analysis module in Matlab 7 (Mathworks) using the average-linkage option.  
Cell Lines  
Primary human embryonic lung fibroblasts (WI-38) were maintained in MEM supplemented 
with 10% fetal calf serum, 1mM sodium-Pyruvate, 2mM L-Glutamine, and antibiotics. Cells were 
passaged and counted once in five to seven days. Population doublings (PDLs) were calculated using 
the formula: PDLs = log(cell output/cell input)/log2. Doubling rates for the indicated culture stages 
were calculated by dividing the PDLs by the corresponding number of days in culture. The HCT-116 
colon carcinoma cell line and its p53-null and p21-null derivatives were a gift from B.Vogelstein (The 
John Hopkins University, Baltimore, MD) and were described in (Bunz et al., 1998).  HCT-116 cells 
were maintained in McCoy’s medium supplemented with 10% fetal calf serum, 1mM sodium-Pyruvate, 
2mM L-Glutamine, and antibiotics. All cell lines were grown at 37°C in a humidified atmosphere of 
5% CO2 in air. 
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Plasmids 
The luciferase reporter construct, p-cdc20-luc, was generated by cloning cdc20 promoter and 5'-
UTR into a luciferase reporter plasmid. Briefly, a genomic fragment of the cdc20 promoter, spanning 
from (-1002) bp to (+229) bp relative to the TSS, was amplified by PCR with the primers 5'- 
tccacctctgagcacattcat-3', 5'- tccttgcagttggtgcct-3', using Expand Long Template PCR system (Roche 
Applied Science). The amplified region was cloned into pGEM-T easy vector (Promega) and then 
transferred into pGL3 super basic vector (gift from M. Oren, Weizmann Institute of Science) using the 
restriction enzymes NdeI and NcoI. Mutations in NF-Y motifs were generated on the template of p-
cdc20-luc using QuikChange Site–Directed Mutagenesis kit (Stratagene) together with the following 
primers (only sense primers are shown, mutations are in uppercase): for mutation of NF-Y motif at 
position (-83), CccttcgccggagaggTAGTAgggctagggcaacggttgc, for mutation of NF-Y motif at position 
(-38), GacggttggattttgaaggagAAGTAaggcgctcggagcggagagt. Expression plasmids for wild-type human 
p53 and mutants L22Q/W23S were gifts of C.Hurris (National Institutes of Health, Bethesda, USA) and were 
described in (Zhou et al., 1999). Expression plasmid for the p53 dominant-negative peptide (p53-DD) 
was a gift of M.Oren and was described in (Shaulian et al., 1992). Expression plasmid for p16 was 
kindly provided by R.Agami (Netherlands Cancer Institute). E2F-dTA expression plasmid 
pRcCMVE2F1-(1–363), encoding a dominant negative form of the E2F transcription factors, was as 
described in (Hofmann et al., 1996). dnNF-YA Expression plasmid NF-YA13m29, encoding a 
dominant negative form of the NF-Y transcription factor subunit A, was described in (Mantovani et al., 
1994).  
Transfections and Reporter Assays  
HCT116 cells were plated at 3*104 cells/well in a 24-well plate 48 hours before transfection. 
Cells were transfected with JetPEI transfection reagent (Polyplus Transfection), using 150 ng/well of 
luciferase reporter construct, 50 ng/well of pCMV-β-galactosidase expression vector for normalization 
of transfection efficiency, and appropriate expression plasmids for a total DNA amount of 1µg/well. 
The p53 expression plasmids were transfected at 10 ng/well. The p16, dnNF-YA and E2F-dTA 
expression plasmids were transfected at 300 ng/well. Cell extracts were prepared 48 hours after 
transfection, and luciferase and β-galactosidase activities were determined using commercial reagents 
and procedures (Promega). Statistical significance was determined by the paired t-test. 
RNA Preparation, cDNA Synthesis and qPCR 
Total RNA was extracted with Versagene RNA cell kit (Gentra Systems, Inc., Minneapolis, 
MN) and treated with DNase (Versagene DNase treatment kit, Gentra Systems, Inc.) following the 
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manufacturer’s instructions. A 2µg aliquot of the total RNA was reverse transcribed using MMLV-RT 
(Promega) and random hexamer primers (Roche Applied Science). Quantitative Real-time PCR 
(qPCR) was performed using SYBR Green PCR Master Mix (Applied Biosystems). The expression 
level for each sample was normalized to that of the GAPDH housekeeping gene in the same sample. 
Primer sequences were as follows: GAPDH, 5'-agcctcaagatcatcagcaatg-3' and 5'-
cacgataccaaagttgtcatggat-3'; cdc20, 5'-gagggtggctgggttcctct-3' and 5'-cagatgcgaatgtgtcgatca-3'; CCNF, 
5'-catctgcacccggtttatca-3' and 5'-cttccaaggcggagacga-3'; BIRC5, 5'-tcatccactgccccactga-3' and 5'-
agaagaaacactgggccaagtc-3'; MAD2L1, 5'-gttggaagtttcttgttcatttgatct-3' and 5'-ggtcccgactcttcccattt-3'; 
CENPF, 5'-agaaagcagtcatgagtggtattca-3' and 5'-gcaggatatatgggctagtctttcc-3'; PRC1, 5'-
acaaaccgaggaggaaatcttct-3' and 5'-caattcgtgccttcaactcttct-3'; Bub1b, 5'-tacactggaaatgaccctctggat-3' and 
5'-tataatatcgtttttctccttgtagtgctt-3'. 
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Figure Legends 
Figure 1 A. Outline of the malignant transformation process. Schematic representation of the 
spontaneous (young, senescent, immortal, tumorigenic, INK4A methylation) and induced (hTERT, H-
Ras, p53 inactivation) modifications of the WI-38 cells along the process of malignant transformation. 
The stages chosen for microarray profiling are indicated by boxes with numerals corresponding to 
columns in the expression matrix shown in B. The time scale of the process is depicted by a horizontal 
axis, and the corresponding population doublings represented by PDLs.  B. The normalized expression 
levels of the 168 genes in the proliferation cluster at twelve stages spanning the transformation process. 
Normalized expression level is color-coded according to the color bar on the right. The table below the 
matrix contains the following information on each sample: days in culture, geometric mean and 
standard deviation of expression level of the cluster’s genes, doubling rate (cell cycle doublings/day) of 
cells at selected stages, activity of hTERT (designated as '+' for all samples following hTERT 
overexpression), activity of p53, as inferred from the application of its dominant-negative peptide, 
GSE56 (‘-‘ indicates expression of GSE56). Here and throughout the paper the following cell line 
designations are introduced: cells are either young, or senescent; grow slow or fast; a sample name 
followed by ‘G’ denotes the application of GSE56; T before sample names indicates the presence of the 
immortalizing telomerase; R following the samples name indicates the insertion of Ras.  
Figure 2 Motif positional bias in promoters of the proliferation cluster genes. The preferred window 
position of the five regulatory motifs, NFY.01, CDE, CHR, ELK1, and E2F.02 in the promoters of the 
proliferation cluster genes is shown. The CHR motif has also a clear strand bias (depicted by a 
directional arrow here), for more details see Fig. S6. 
Figure 3 A. Graph depicting interaction between the five regulatory motifs measured by synergy and 
co-occurrence. A pair of motifs connected by a thick red line have a synergistic effect on expression 
and pairs connected by a thin blue line are significantly more highly co-occurring in individual 
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promoters. These interactions were computed using all genes on the array. In addition we calculated 
co-occurrence interaction given only the genes in the cluster (i.e. considering the total number of genes 
in the cluster and the number of cluster’s genes containing each motif as a background), and found 
even there several significant interactions (blue dotted lines). Since for some of the motifs, the motif 
database contains multiple variants, we unified all variants of the same motif into one node, and an 
edge in the graph connects between two motifs if at least one of the variants of the two motifs are either 
synergistic or highly co-occurring. B-C. Combinogram analyses (Pilpel et al., 2001) using the five 
regulatory motifs during the transformation process (B) and HeLa cell cycle (C). All the varying genes 
in the respective arrays were used in the analysis. The upper and middle parts of the Combinogram are 
depicted as before (Pilpel et al., 2001), while the lower part is modified. Briefly, the middle section of 
the Combinogram depicts the motif composition of each gene set defined by Motif Combination 
(GMC, see Methods). Each vertical column represents a single GMC. A black square indicates that the 
particular motif is present in the promoters of all the genes in that GMC. A white square indicates that 
none of the genes in the GMC contain the particular motif. The top section of the graph shows the 
dendrogram analysis that assesses the similarity in expression profiles of each GMC using normalized 
Euclidean distances between the average expression profiles of the genes in the GMC as a measure of 
distance. The lower part of this modified Combinogram displays the mean expression profiles of the 
genes in each GMC, color-coded as in Fig. 1. The numbers of genes in each GMC appear below the 
dendrogram. The three main branch points in the dendrogram in B are represented as 1-3 (in circles). In 
the present analysis only genes that contain the motifs in their preferred distance relative to TSS (as 
depicted in Fig. 2) were considered, as genes that contain the motifs, yet away from the preferred 
location interestingly display no clear expression patterns (not shown). Since CHR motif has a strong 
strand bias in addition, and since genes that contain this motif yet on the non-preferred strand have a 
non-coherent expression profile (Fig. S6), for this motif we considered only genes that contain it in the 
preferred strand and distance from the TSS.  
Figure 4 A. Normalized expression profiles of the tumor-suppressors p21 (brown line) and p16 (black 
line), along with a profile that represents the average of their profiles (green area), and a profile that 
represents the mean expression profiles of the genes in the proliferation cluster (blue area). B. Average 
expression profiles of all genes in the genome that contain Elk1 in their promoters (left) and the NFY 
and CHR motifs (right). Each bar represents an average over the samples that corresponds to low 
expression (<-0.3) denoted by ‘L’, and high expression (> 0.2) denoted by ‘H’ of the normalized 
mRNA expression levels of p21 and p16.  
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Figure 5 Three-way linkage between expression profiles, promoter architecture and tumor suppressor 
pathways. A. The entire expression matrix of the proliferation cluster genes, sorted with SPIN (Tsafrir 
et al., 2005), revealing an “elongated” shape for this cluster. B. Correlation coefficient between p21 and 
between p16 expression profiles to each of the genes in the cluster, color-coded according to color bar 
shown. C. Cumulative distribution of CHR, ELK1, and NFY along the sorted list of genes in A. D. 
Bars depicting main areas of density of regulatory motifs along the sorted expression matrix in A., are 
based on cumulative appearance in C. and E. Arrows in the networks represent positive (green) or 
negative (red) interactions. Reviewed in: 1. (Ullrich and Schlessinger, 1990) 2. (Gille et al., 1995) 3. 
(Lin et al., 1998; Serrano. M et al., 1997; Zhu et al., 1998) 4,5,7,9-11 are reviewed in (Hahn and 
Weinberg, 2002; Sherr, 1996; Sherr and Roberts, 1999; Weinberg, 1995) 6. (el-Deiry et al., 1993) 8. 
(Yun et al., 2003); 12. Newly proposed interaction (this paper). 
Figure 6 p53 represses proliferation cluster genes expression following DNA damage. Normal and 
GSE56-expressing WI-38 cells were treated with 0.2 µg/ml doxorubicin (dox) for 48 hours. mRNA 
levels for the indicated genes (y-axis) were measured by qPCR and normalized to the GAPDH 
housekeeping control.  
Figure 7 A. The cdc20 promoter is repressed by wild-type p53 and by p16, but not by a transactivation 
deficient p53 mutant. Normalized luciferase activity of the p-cdc20-luc reporter in HCT-116 p53-/- 
cells. cdc20 promoter activity in the absence (control) or presence of either wild-type p53 (wt-p53), the 
L22Q/W23S p53 mutant (p53 22,23), or p16. B. cdc20 promoter is regulated by E2F and NF-Y. 
Normalized luciferase activity of p-cdc20-luc reporter in HCT-116 p53-/- cells. cdc20 promoter 
activity in the absence or presence of wild-type p53 and in the presence of either control vector 
(control), dominant-negative E2F1 (E2F-dTA), or dominant-negative NF-YA (dnNF-YA). Fold 
repression was calculated as the ratio of promoter activity in the absence of wt-p53 to the level in its 
presence, and was significantly lower in the presence of dominant-negative E2F1 and dominant-
negative NF-YA compared to control (paired t-test p-values = 0.03 and 0.01, respectively). C. NF-Y 
motifs are important for p53-mediated repression of the cdc20 promoter. The wild type promoter 
construct p-cdc20-luc and a construct with both NF-Y motifs mutated (mutant NF-Y 1+2) were 
cotransfected into HCT116 p53+/+ cells in the presence or absence of a dominant-negative p53 (p53-
DD). Fold repression was calculated as the ratio of promoter activity in the presence of p53-DD to 
control and was significantly lower for the mutant NF-Y 1+2 construct (p-value = 0.005). Data 
represent the average of three independent experiments, each performed in triplicate.  
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Supporting Information 
Supplemental Data 1. Microarray-derived expression levels of 168 genes of the proliferation cluster 
along the 12 time-points (each in duplicate) of the in-vitro transformation.  
Supplementary Figure 1. Properties of the proliferation cluster. 
Supplementary Figure 2. Expression profiles of 53 proliferation cluster genes during three human cell 
cycles (Whitfield et al., 2002). 
Supplementary Figure 3. Evolutionary conservation of motifs and promoter architecture between 
human and mouse proliferation cluster-derived orthologous promoters. 
Supplementary Figure 4. Negative correlation between the proliferation cluster genes expression level 
and the sum-gate of p16 and p21. 
 
Supplementary Figure 5. An annotation-based procedure to determine a threshold score in assigning 
genes to a PSSM. 
 
Supplementary Figure 6. Only genes that contain the CHR motif in its preferred strand and location 
display the proliferation signature. 
Supplementary Table 1. Functional categories enriched in the proliferation cluster. 
Supplementary Table 2. 5'-UTR analysis of the proliferation cluster genes. 
Supplementary Table 3. Enriched motifs of the proliferation cluster are also over-represented in 
orthologous mouse promoters.  
Supplementary Table 4. Promoter motif content of ~33,000 genes that are not represented on the 
Focus Array. 
Supplementary Table 5. Over-representation p-values of all the MatInspector motifs in the 
proliferation cluster. 
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Table I. Over-represented regulatory motifs in the proliferation cluster.  
 
Motif 
Number of genes containing motif 
among the proliferation cluster/entire 
array 
Over representation p-value 
NFY 77/1574 9.92E-12 
E2F 85/2617 3.57E-07 
CDE 101/3073 2.20E-09 
ELK1 38/960 4.32E-05 
CHR 10/63 5.43E-07 
CHR-NFY-CDE 9/12 1.18E-13 
 
The number of genes that contain the corresponding motif in their promoter among the proliferation 
cluster (out of 165 genes) and among the entire array (out of 8110 genes). A hyper-geometric p-value 
score was calculated in order to assess the extent to which a motif is over represented in significant 
location among the cluster’s genes compared to the rest of the genes on the array.  
 
 
Table II. p53- and p21- dependent repression of the proliferation cluster genes expression.  
 
 Fold Repression 
Gene Symbol HCT116 p53+/+ 
HCT116 
p53-/- 
HCT116 
p21-/- 
Cdc20 2.6 1.2 0.7 
BIRC5 1.6 0.6 0.7 
NEK2 1.8 0.5 0.9 
Mad2L1 2.4 0.7 0.8 
Bub1B 1.7 0.8 1.1 
PRC1 1.7 0.9 0.9 
CENPF 1.7 0.7 1.2 
 
HCT-116 cells containing wild type p53 and their p53-null and p21-null derivatives were treated with 
0.2 µg/ml doxorubicin for 48 hours. The expression level for each gene was measured by qPCR and 
normalized to GAPDH expression level. The numbers in the table represent fold repression, calculated 
for each gene as the ratio of expression level in non-treated cells to doxorubicin-treated cells. 
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